Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) rose 5.9% during trading on Tuesday . The company traded as high as $3.38 and last traded at $3.31. Approximately 1,090,048 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 2,201,736 shares. The stock had previously closed at $3.12.
Analyst Upgrades and Downgrades
MRVI has been the subject of a number of recent research reports. Royal Bank Of Canada reduced their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of Maravai LifeSciences in a research report on Saturday, September 27th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $5.22.
Read Our Latest Report on Maravai LifeSciences
Maravai LifeSciences Stock Performance
The firm's 50 day simple moving average is $2.57 and its 200 day simple moving average is $2.34. The firm has a market capitalization of $849.08 million, a price-to-earnings ratio of -2.46 and a beta of 0.33. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.49 and a current ratio of 5.16.
Institutional Trading of Maravai LifeSciences
Institutional investors have recently modified their holdings of the stock. Orion Porfolio Solutions LLC raised its stake in Maravai LifeSciences by 34.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 321,879 shares of the company's stock valued at $776,000 after purchasing an additional 82,522 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Maravai LifeSciences by 121.1% in the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company's stock worth $43,000 after buying an additional 9,870 shares in the last quarter. Lazard Asset Management LLC boosted its position in Maravai LifeSciences by 3.1% during the second quarter. Lazard Asset Management LLC now owns 1,450,421 shares of the company's stock worth $3,495,000 after acquiring an additional 44,128 shares during the last quarter. Engineers Gate Manager LP raised its holdings in Maravai LifeSciences by 21.6% in the 2nd quarter. Engineers Gate Manager LP now owns 190,137 shares of the company's stock valued at $458,000 after acquiring an additional 33,712 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Maravai LifeSciences by 17.2% in the 2nd quarter. Bank of America Corp DE now owns 1,029,645 shares of the company's stock worth $2,481,000 after purchasing an additional 151,205 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company's stock.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
